← Back

Wire · operational-macro

FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis

Published

17 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA has accepted a supplemental new drug application for the combination of selinexor and ruxolitinib in treating myelofibrosis, based on the phase 3 SENTRY trial showing significant spleen volume reduction and improved overall survival signals. The review targets a potential first approved combination therapy beyond existing JAK inhibitor monotherapy with a decision expected by June 28, 2027.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now prepare for a new FDA regulatory pathway opening in myelofibrosis with a combination treatment that could reshape treatment standards. Trial success signals an opening to target patients beyond JAK inhibitor monotherapy.

◆ Coverage

1 source · 17 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDAdrug-approvalmyelofibrosisclinical-trialselinexorruxolitinib